rhPro-UK in Acute Ischaemic Stroke Within 4.5 Hours of Stroke Onset Trial 2(PROST-2)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1552 participants.
Also called NCT05700591
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,552 participants
- Sponsor
- Tasly Biopharmaceuticals Co., Ltd.
- Registry
-
NCT05700591
-
- Other papers using this trial's data
- Safety and efficacy of intravenous recombinant human prourokinase for acute ischaemic stroke within 4·5 h after stroke onset (PROST-2): a phase 3, open-label, non-inferiority, randomised controlled trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT05700591. Randomized; single masking; primary purpose treatment. Start 2023-01-29 (actual); primary completion 2024-03-14 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- rhPro-UK in Acute Ischaemic Stroke Within 4.5 Hours of Stroke Onset Trial 2(PROST-2)
- Acronym
- PROST-2
- Condition
- Acute Ischemic Stroke
- Intervention (Drug)
- rhPro-UK
- Intervention (Drug)
- rt-PA
- Lead sponsor
- Tasly Biopharmaceuticals Co., Ltd.
Record details
- Record id
cardio:ct-nct05700591- Content hash
f26710cbbb14617f1965f2ef8750aca8525114592f421796c9457130600558e0